NCT03134586

Brief Summary

The purpose of this study is to determine whether Non-invasive endoscopic procedures (pillcam colon capsule endoscopy, PCCE) and non-ionizing radiological modalities (MR enterocolonography, MREC and ultrasound, US) - offer a sufficiently high diagnostic validity in patients with suspected CD compared to the traditional invasive approach using ileocolonoscopy with biopsies as first line diagnostic modality

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
153

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2016

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

January 6, 2017

Completed
4 months until next milestone

First Posted

Study publicly available on registry

May 1, 2017

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2020

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 23, 2020

Completed
Last Updated

November 1, 2022

Status Verified

October 1, 2022

Enrollment Period

4.3 years

First QC Date

January 6, 2017

Last Update Submit

October 31, 2022

Conditions

Keywords

Capsule endoscopyCrohn's diseaseMagnetic resonance enterographyIleocolonoscopyBowel Ultrasounddiagnostic imaging

Outcome Measures

Primary Outcomes (3)

  • Sensitivity and specificity of PCCE, MREC and US for the diagnosis of CD

    Sensitivity and specificity of PCCE, MREC and US for the diagnosis of CD located in the terminal ileum and colon (per patient \& per segment). Ileocolonoscopy serves as gold standard

    36 months

  • Correlation of disease severity

    Correlation of disease severity assessed with PCCE, MREC, US and ileocolonoscopy

    36 months

  • Inter-observer agreement

    Inter-observer agreement with PCCE, MREC, US and ileocolonoscopy

    36 months

Secondary Outcomes (4)

  • Diagnostic yield of proximal CD

    36 months

  • Patients reported experience

    36 months

  • Interobserver PCCE

    36 months

  • Utility of diffusion weighed magnetic resonance imaging (dw-MREC) and US Doppler flow

    36 months

Study Arms (1)

trial participant

OTHER

All participants undergoes the same diagnostic imaging

Other: Diagnostic imaging

Interventions

trial participant

Eligibility Criteria

Age15 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • General criterion
  • All of the following:
  • Clinical suspicion of CD
  • Age \> 15 years
  • Negative serologic markers for celiac disease, negative stool culture (or polymerase chain reaction) for pathogenic bacteria and a negative microscopy for intestinal parasites
  • Fecal calprotectin \> 50 mg/kg
  • Signed informed consent
  • Clinical criterion Diarrhea and/or abdominal pain for more than 1 month (or repeated episodes of diarrhea and/or abdominal pain) associated with one or more of the following findings: (1) C-reactive protein (CRP) \>5 mg/L, (2) thrombocytosis (\> 400 x 109/L), anemia (hemoglobin \< 7.0 mmol/L for women and \< 8.0 mmol /L for men or a decrease \> 0.5 mmol/L compared to the usual level), (3) prolonged fever (\> 37.5 C for more than 2 weeks), (5) weight loss (≥ 3 kg or ≥ 5% compared to the normal body weight), (6) perianal abscess/fistula, or (7) a family history of inflammatory bowel disease.

You may not qualify if:

  • Acute bowel obstruction
  • Pregnancy or lactation
  • Alcohol or drug abuse
  • Known gastrointestinal disorder other than inflammatory bowel disease
  • Renal failure defined by a plasma-creatinine above the normal reference range
  • Claustrophobia, cardiac pacemaker or implanted magnetic foreign bodies that precludes MREC
  • Interpreter required or inability to understand the oral and written information
  • Colonoscopy contraindicated, performed within 3 months or unwillingness to go through colonoscopy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Sydvestjysk sygehus

Esbjerg, DK-6700, Denmark

Location

Odense university Hospital

Odense, DK-5000, Denmark

Location

Sygehus Lillebaelt

Vejle, DK-7100, Denmark

Location

Related Publications (2)

  • Brodersen JB, Jensen MD, Juel MA, Kjeldsen J, Knudsen T, Rafaelsen SR. Intestinal ultrasound in patients with suspected Crohn's disease - results of a prospective evaluation by trainees. Scand J Gastroenterol. 2023 Jul-Dec;58(12):1405-1411. doi: 10.1080/00365521.2023.2234538. Epub 2023 Jul 17.

  • Brodersen JB, Knudsen T, Kjeldsen J, Juel MA, Rafaelsen SR, Jensen MD. Diagnostic accuracy of pan-enteric capsule endoscopy and magnetic resonance enterocolonography in suspected Crohn's disease. United European Gastroenterol J. 2022 Nov;10(9):973-982. doi: 10.1002/ueg2.12307. Epub 2022 Sep 7.

MeSH Terms

Conditions

Crohn Disease

Interventions

X-Rays

Condition Hierarchy (Ancestors)

Inflammatory Bowel DiseasesGastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal Diseases

Intervention Hierarchy (Ancestors)

Electromagnetic RadiationElectromagnetic PhenomenaMagnetic PhenomenaPhysical PhenomenaRadiationRadiation, Ionizing

Study Officials

  • Jacob B Brodersen, MD

    Esbjerg Hospital - University Hospital of Southern Denmark

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Specialist Registrat

Study Record Dates

First Submitted

January 6, 2017

First Posted

May 1, 2017

Study Start

June 1, 2016

Primary Completion

August 31, 2020

Study Completion

October 23, 2020

Last Updated

November 1, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will not share

Locations